Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.97% | -9,637.90% | 1,204.51% | 340.97% | 2,496.63% |
| Total Depreciation and Amortization | 3.09% | -1.76% | -13.06% | -8.03% | -0.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 251.21% | 122.14% | -23.70% | 766.05% | -128.35% |
| Change in Net Operating Assets | 495.87% | 0.30% | -359.83% | -126.58% | 93.72% |
| Cash from Operations | 64.31% | -20.32% | -1.23% | 49.18% | 288.75% |
| Capital Expenditure | -610.94% | -31.85% | -691.67% | -33.33% | 59.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.87% | 173.27% | 81.18% | -320.82% | -180.27% |
| Cash from Investing | 37.01% | 172.29% | 80.85% | -322.36% | -180.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 97.47% | -29.83% | 529.76% | 367.84% | -34.22% |
| Repurchase of Common Stock | -4,500.00% | -149.33% | -- | 60.10% | 99.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -43.61% | -1,462.99% | 439.38% | 1,436.96% | 100.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 355.15% | 499.18% | 288.94% | -129.05% | 97.41% |